$12.5 Billion is the total value of FARALLON CAPITAL MANAGEMENT LLC's 119 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TMUS | New | T-MOBILE US INC | $360,112,000 | – | 3,457,631 | +100.0% | 2.88% | – |
| AON | New | AON PLC | $331,368,000 | – | 1,720,498 | +100.0% | 2.65% | – |
| WUBA | New | 58 COM INCspon adr rep a | $267,824,000 | – | 4,965,212 | +100.0% | 2.14% | – |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $213,150,000 | – | 3,625,000 | +100.0% | 1.71% | – |
| TIF | New | TIFFANY & CO NEW | $186,287,000 | – | 1,527,698 | +100.0% | 1.49% | – |
| NYT | New | NEW YORK TIMES COcl a | $173,901,000 | – | 4,137,542 | +100.0% | 1.39% | – |
| CZR | New | CAESARS ENTMT CORP | $97,222,000 | – | 8,015,000 | +100.0% | 0.78% | – |
| EDU | New | NEW ORIENTAL ED & TECHNOLOGYspon adr | $82,175,000 | – | 631,000 | +100.0% | 0.66% | – |
| New | MOMO INCnote 1.250% 7/0 | $64,159,000 | – | 81,601,000 | +100.0% | 0.51% | – | |
| New | IQIYI INCnote 2.000% 4/0 | $61,445,000 | – | 61,438,000 | +100.0% | 0.49% | – | |
| ARNA | New | ARENA PHARMACEUTICALS INC | $56,655,000 | – | 900,000 | +100.0% | 0.45% | – |
| ZNTL | New | ZENTALIS PHARMACEUTICALS INC | $47,596,000 | – | 991,174 | +100.0% | 0.38% | – |
| GBIO | New | GENERATION BIO CO | $44,495,000 | – | 2,118,819 | +100.0% | 0.36% | – |
| LNTH | New | LANTHEUS HLDGS INC | $37,680,000 | – | 2,634,999 | +100.0% | 0.30% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $33,187,000 | – | 1,844,757 | +100.0% | 0.27% | – |
| New | IQIYI INCnote 3.750%12/0 | $33,097,000 | – | 29,500,000 | +100.0% | 0.26% | – | |
| AMRS | New | AMYRIS INC | $29,931,000 | – | 7,009,527 | +100.0% | 0.24% | – |
| New | HORIZON PHARMA INVT LTDnote 2.500% 3/1 | $29,367,000 | – | 15,047,000 | +100.0% | 0.24% | – | |
| TGTX | New | TG THERAPEUTICS INC | $29,220,000 | – | 1,500,000 | +100.0% | 0.23% | – |
| PLRX | New | PLIANT THERAPEUTICS INC | $27,617,000 | – | 850,801 | +100.0% | 0.22% | – |
| ADAP | New | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $25,025,000 | – | 2,500,000 | +100.0% | 0.20% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $24,740,000 | – | 1,000,000 | +100.0% | 0.20% | – |
| FXI | New | ISHARES TRput | $22,331,000 | – | 562,500 | +100.0% | 0.18% | – |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $20,022,000 | – | 20,000,000 | +100.0% | 0.16% | – | |
| HWM | New | HOWMET AEROSPACE INC | $19,007,000 | – | 1,199,186 | +100.0% | 0.15% | – |
| LQDA | New | LIQUIDIA TECHNOLOGIES INC | $15,577,000 | – | 1,850,000 | +100.0% | 0.12% | – |
| RPRX | New | ROYALTY PHARMA PLC | $13,351,000 | – | 275,000 | +100.0% | 0.11% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $10,518,000 | – | 350,000 | +100.0% | 0.08% | – |
| ATTO | New | ATENTO S A | $7,712,000 | – | 11,212,205 | +100.0% | 0.06% | – |
| AKUS | New | AKOUOS INC | $5,063,000 | – | 225,000 | +100.0% | 0.04% | – |
| AMTI | New | APPLIED MOLECULAR TRANS INC | $5,028,000 | – | 200,000 | +100.0% | 0.04% | – |
| ARYBU | New | ARYA SCIENCES ACQUISTION COunit 06/09/2027 | $4,640,000 | – | 400,000 | +100.0% | 0.04% | – |
| RPTX | New | REPARE THERAPEUTICS INC | $4,653,000 | – | 150,000 | +100.0% | 0.04% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC | $4,368,000 | – | 250,000 | +100.0% | 0.04% | – |
| ISEE | New | IVERIC BIO INC | $3,825,000 | – | 750,000 | +100.0% | 0.03% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $1,413,000 | – | 50,000 | +100.0% | 0.01% | – |
| CTMX | New | CYTOMX THERAPEUTICS INC | $1,241,000 | – | 148,952 | +100.0% | 0.01% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MICROSOFT CORP | 41 | Q3 2023 | 3.7% |
| RADIUS HEALTH INC | 33 | Q2 2022 | 1.7% |
| GRIFOLS S A | 33 | Q4 2021 | 0.9% |
| ALPHABET INC | 32 | Q3 2023 | 4.2% |
| SPDR S&P 500 ETF TR | 31 | Q3 2023 | 25.3% |
| VISA INC | 30 | Q3 2023 | 2.9% |
| WABTEC CORP | 27 | Q3 2023 | 3.6% |
| EXELIXIS INC | 27 | Q3 2023 | 2.8% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 2.6% |
| SAVARA INC | 26 | Q3 2023 | 0.3% |
View FARALLON CAPITAL MANAGEMENT LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Atento S.A. | March 15, 2023 | 2,230,357 | 15.4% |
| Metals Acquisition Corp | February 07, 2023 | 2,489,700 | 9.4% |
| Inflection Point Acquisition Corp. | February 06, 2023 | 1,900,000 | 5.8% |
| AMYRIS, INC. | February 24, 2022 | 1,068,904 | 0.3% |
| Swiftmerge Acquisition Corp. | February 14, 2022 | 291,060 | 1.3% |
| Caribou Biosciences, Inc. | February 11, 2022 | 2,428,150 | 4.0% |
| ENANTA PHARMACEUTICALS INC | February 11, 2022 | 287,000 | 1.4% |
| Protagonist Therapeutics, Inc | February 11, 2022 | 387,051 | 0.8% |
| Solid Power, Inc. | February 11, 2022 | ? | ? |
| Better Therapeutics, Inc. | February 09, 2022 | 124,065 | 0.5% |
View FARALLON CAPITAL MANAGEMENT LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| 13F-HR/A | 2024-02-12 |
| SC 13G/A | 2024-02-01 |
| SC 13G/A | 2024-01-23 |
View FARALLON CAPITAL MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.